MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.580
+0.140
+5.74%
After Hours: 2.580 0 0.00% 16:00 04/07 EDT
OPEN
2.500
PREV CLOSE
2.440
HIGH
2.730
LOW
2.430
VOLUME
610.01K
TURNOVER
--
52 WEEK HIGH
6.04
52 WEEK LOW
1.600
MARKET CAP
142.45M
P/E (TTM)
-4.5850
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PIRS stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 5.00.

EPS

PIRS News

More
  • Edited Transcript of PIRS earnings conference call or presentation 12-Mar-20 12:00pm GMT
  • Thomson Reuters StreetEvents · 03/30 11:08
  • Biotech stocks have held up better than the broader market and these five are potential winners
  • MarketWatch · 03/24 21:23
  • Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
  • ACCESSWIRE · 03/24 21:00
  • Pieris Pharmaceuticals Provides Update on Servier Collaboration
  • ACCESSWIRE · 03/23 21:30

Industry

Biotechnology & Medical Research
-2.20%
Pharmaceuticals & Medical Research
-1.62%

Hot Stocks

Symbol
Price
%Change

About PIRS

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
More

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.